PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma.
Purpose Palifosfamide is the active metabolite of ifosfamide and does not require prodrug activation, thereby avoiding the generation of toxic metabolites. The PICASSO III trial compared doxorubicin plus palifosfamide with doxorubicin plus placebo in patients who had received no prior systemic therapy for metastatic soft tissue sarcoma. Patients and Methods Patients were randomly assigned 1:1 to receive doxorubicin 75 mg/m2intravenously day 1 plus palifosfamide 150 mg/m2/d intravenously days 1 to 3 or doxorubicin plus placebo once every 21 days for up to six cycles. The primary end point was progression-free survival (PFS) by independent radiologic review. Results In all, 447 patients were randomly assigned to receive doxorubicin plus palifosfamide (n = 226) or doxorubicin plus placebo (n = 221). Median PFS was 6.0 months for doxorubicin plus palifosfamide and 5.2 months for doxorubicin plus placebo (hazard ratio, 0.86; 95% CI, 0.68 to 1.08; P = .19). Median overall survival was 15.9 months for doxorubicin plus palifosfamide and 16.9 months for doxorubicin plus placebo (hazard ratio, 1.05; 95% CI, 0.79 to 1.39; P = .74). There was a higher incidence of grade 3 to 4 adverse events in the doxorubicin plus palifosfamide arm (63.6% v 50.9%) including a higher rate of febrile neutropenia (21.4% v 12.6%). Conclusion No significant difference in PFS was observed in patients receiving doxorubicin plus palifosfamide compared with those receiving doxorubicin plus placebo. The observed median PFS and overall survival in this large, international study can serve as a benchmark for future studies of doxorubicin in metastatic soft tissue sarcoma.
Christopher W. Ryan, Oregon Health & Science University, Portland, OR; Ofer Merimsky, Sackler School of Medicine, Tel-Aviv, Israel; Mark Agulnik, Northwestern University, Chicago, IL; Jean-Yves Blay, Centre Léon Bérard, Lyon; Antoine Italiano, Institut Bergonié, Bordeaux, France; Scott M. Schuetze, University of Michigan, Ann Arbor, MI; Brian A. Van Tine, Washington University in St Louis, St Louis, MO; Robin L. Jones and Ian R. Judson, The Royal Marsden Hospital, London, United Kingdom; Anthony D. Elias, University of Colorado-Denver, Aurora, CO; Edwin Choy, Massachusetts General Hospital; Jill Y. Buck and Francois Lebel, ZIOPHARM Oncology, Boston, MA; Thierry Alcindor, McGill University Health Center, Montreal, Quebec, Canada; Vicki L. Keedy, Vanderbilt University Medical Center, Nashville, TN; Damon R. Reed, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Robert N. Taub, Columbia University Medical Center; Jonathan J. Lewis, Samus Therapeutics and Molecular Ninja Group; Robert G. Maki, Mount Sinai School of Medicine, New York, NY; Xavier Garcia del Muro, Institut Català d'Oncologia L'Hospitalet, Barcelona, Spain; and Patrick Schöffski, University Hospitals Leuven, Leuven, Belgium.
Christopher W
CW
Ryan
Christopher W. Ryan, Oregon Health & Science University, Portland, OR; Ofer Merimsky, Sackler School of Medicine, Tel-Aviv, Israel; Mark Agulnik, Northwestern University, Chicago, IL; Jean-Yves Blay, Centre Léon Bérard, Lyon; Antoine Italiano, Institut Bergonié, Bordeaux, France; Scott M. Schuetze, University of Michigan, Ann Arbor, MI; Brian A. Van Tine, Washington University in St Louis, St Louis, MO; Robin L. Jones and Ian R. Judson, The Royal Marsden Hospital, London, United Kingdom; Anthony D. Elias, University of Colorado-Denver, Aurora, CO; Edwin Choy, Massachusetts General Hospital; Jill Y. Buck and Francois Lebel, ZIOPHARM Oncology, Boston, MA; Thierry Alcindor, McGill University Health Center, Montreal, Quebec, Canada; Vicki L. Keedy, Vanderbilt University Medical Center, Nashville, TN; Damon R. Reed, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Robert N. Taub, Columbia University Medical Center; Jonathan J. Lewis, Samus Therapeutics and Molecular Ninja Group; Robert G. Maki, Mount Sinai School of Medicine, New York, NY; Xavier Garcia del Muro, Institut Català d'Oncologia L'Hospitalet, Barcelona, Spain; and Patrick Schöffski, University Hospitals Leuven, Leuven, Belgium.
Ofer
O
Merimsky
Christopher W. Ryan, Oregon Health & Science University, Portland, OR; Ofer Merimsky, Sackler School of Medicine, Tel-Aviv, Israel; Mark Agulnik, Northwestern University, Chicago, IL; Jean-Yves Blay, Centre Léon Bérard, Lyon; Antoine Italiano, Institut Bergonié, Bordeaux, France; Scott M. Schuetze, University of Michigan, Ann Arbor, MI; Brian A. Van Tine, Washington University in St Louis, St Louis, MO; Robin L. Jones and Ian R. Judson, The Royal Marsden Hospital, London, United Kingdom; Anthony D. Elias, University of Colorado-Denver, Aurora, CO; Edwin Choy, Massachusetts General Hospital; Jill Y. Buck and Francois Lebel, ZIOPHARM Oncology, Boston, MA; Thierry Alcindor, McGill University Health Center, Montreal, Quebec, Canada; Vicki L. Keedy, Vanderbilt University Medical Center, Nashville, TN; Damon R. Reed, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Robert N. Taub, Columbia University Medical Center; Jonathan J. Lewis, Samus Therapeutics and Molecular Ninja Group; Robert G. Maki, Mount Sinai School of Medicine, New York, NY; Xavier Garcia del Muro, Institut Català d'Oncologia L'Hospitalet, Barcelona, Spain; and Patrick Schöffski, University Hospitals Leuven, Leuven, Belgium.
Mark
M
Agulnik
Christopher W. Ryan, Oregon Health & Science University, Portland, OR; Ofer Merimsky, Sackler School of Medicine, Tel-Aviv, Israel; Mark Agulnik, Northwestern University, Chicago, IL; Jean-Yves Blay, Centre Léon Bérard, Lyon; Antoine Italiano, Institut Bergonié, Bordeaux, France; Scott M. Schuetze, University of Michigan, Ann Arbor, MI; Brian A. Van Tine, Washington University in St Louis, St Louis, MO; Robin L. Jones and Ian R. Judson, The Royal Marsden Hospital, London, United Kingdom; Anthony D. Elias, University of Colorado-Denver, Aurora, CO; Edwin Choy, Massachusetts General Hospital; Jill Y. Buck and Francois Lebel, ZIOPHARM Oncology, Boston, MA; Thierry Alcindor, McGill University Health Center, Montreal, Quebec, Canada; Vicki L. Keedy, Vanderbilt University Medical Center, Nashville, TN; Damon R. Reed, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Robert N. Taub, Columbia University Medical Center; Jonathan J. Lewis, Samus Therapeutics and Molecular Ninja Group; Robert G. Maki, Mount Sinai School of Medicine, New York, NY; Xavier Garcia del Muro, Institut Català d'Oncologia L'Hospitalet, Barcelona, Spain; and Patrick Schöffski, University Hospitals Leuven, Leuven, Belgium.
Jean-Yves
JY
Blay
Christopher W. Ryan, Oregon Health & Science University, Portland, OR; Ofer Merimsky, Sackler School of Medicine, Tel-Aviv, Israel; Mark Agulnik, Northwestern University, Chicago, IL; Jean-Yves Blay, Centre Léon Bérard, Lyon; Antoine Italiano, Institut Bergonié, Bordeaux, France; Scott M. Schuetze, University of Michigan, Ann Arbor, MI; Brian A. Van Tine, Washington University in St Louis, St Louis, MO; Robin L. Jones and Ian R. Judson, The Royal Marsden Hospital, London, United Kingdom; Anthony D. Elias, University of Colorado-Denver, Aurora, CO; Edwin Choy, Massachusetts General Hospital; Jill Y. Buck and Francois Lebel, ZIOPHARM Oncology, Boston, MA; Thierry Alcindor, McGill University Health Center, Montreal, Quebec, Canada; Vicki L. Keedy, Vanderbilt University Medical Center, Nashville, TN; Damon R. Reed, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Robert N. Taub, Columbia University Medical Center; Jonathan J. Lewis, Samus Therapeutics and Molecular Ninja Group; Robert G. Maki, Mount Sinai School of Medicine, New York, NY; Xavier Garcia del Muro, Institut Català d'Oncologia L'Hospitalet, Barcelona, Spain; and Patrick Schöffski, University Hospitals Leuven, Leuven, Belgium.
Scott M
SM
Schuetze
Christopher W. Ryan, Oregon Health & Science University, Portland, OR; Ofer Merimsky, Sackler School of Medicine, Tel-Aviv, Israel; Mark Agulnik, Northwestern University, Chicago, IL; Jean-Yves Blay, Centre Léon Bérard, Lyon; Antoine Italiano, Institut Bergonié, Bordeaux, France; Scott M. Schuetze, University of Michigan, Ann Arbor, MI; Brian A. Van Tine, Washington University in St Louis, St Louis, MO; Robin L. Jones and Ian R. Judson, The Royal Marsden Hospital, London, United Kingdom; Anthony D. Elias, University of Colorado-Denver, Aurora, CO; Edwin Choy, Massachusetts General Hospital; Jill Y. Buck and Francois Lebel, ZIOPHARM Oncology, Boston, MA; Thierry Alcindor, McGill University Health Center, Montreal, Quebec, Canada; Vicki L. Keedy, Vanderbilt University Medical Center, Nashville, TN; Damon R. Reed, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Robert N. Taub, Columbia University Medical Center; Jonathan J. Lewis, Samus Therapeutics and Molecular Ninja Group; Robert G. Maki, Mount Sinai School of Medicine, New York, NY; Xavier Garcia del Muro, Institut Català d'Oncologia L'Hospitalet, Barcelona, Spain; and Patrick Schöffski, University Hospitals Leuven, Leuven, Belgium.
Brian A
BA
Van Tine
Christopher W. Ryan, Oregon Health & Science University, Portland, OR; Ofer Merimsky, Sackler School of Medicine, Tel-Aviv, Israel; Mark Agulnik, Northwestern University, Chicago, IL; Jean-Yves Blay, Centre Léon Bérard, Lyon; Antoine Italiano, Institut Bergonié, Bordeaux, France; Scott M. Schuetze, University of Michigan, Ann Arbor, MI; Brian A. Van Tine, Washington University in St Louis, St Louis, MO; Robin L. Jones and Ian R. Judson, The Royal Marsden Hospital, London, United Kingdom; Anthony D. Elias, University of Colorado-Denver, Aurora, CO; Edwin Choy, Massachusetts General Hospital; Jill Y. Buck and Francois Lebel, ZIOPHARM Oncology, Boston, MA; Thierry Alcindor, McGill University Health Center, Montreal, Quebec, Canada; Vicki L. Keedy, Vanderbilt University Medical Center, Nashville, TN; Damon R. Reed, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Robert N. Taub, Columbia University Medical Center; Jonathan J. Lewis, Samus Therapeutics and Molecular Ninja Group; Robert G. Maki, Mount Sinai School of Medicine, New York, NY; Xavier Garcia del Muro, Institut Català d'Oncologia L'Hospitalet, Barcelona, Spain; and Patrick Schöffski, University Hospitals Leuven, Leuven, Belgium.
Robin L
RL
Jones
Christopher W. Ryan, Oregon Health & Science University, Portland, OR; Ofer Merimsky, Sackler School of Medicine, Tel-Aviv, Israel; Mark Agulnik, Northwestern University, Chicago, IL; Jean-Yves Blay, Centre Léon Bérard, Lyon; Antoine Italiano, Institut Bergonié, Bordeaux, France; Scott M. Schuetze, University of Michigan, Ann Arbor, MI; Brian A. Van Tine, Washington University in St Louis, St Louis, MO; Robin L. Jones and Ian R. Judson, The Royal Marsden Hospital, London, United Kingdom; Anthony D. Elias, University of Colorado-Denver, Aurora, CO; Edwin Choy, Massachusetts General Hospital; Jill Y. Buck and Francois Lebel, ZIOPHARM Oncology, Boston, MA; Thierry Alcindor, McGill University Health Center, Montreal, Quebec, Canada; Vicki L. Keedy, Vanderbilt University Medical Center, Nashville, TN; Damon R. Reed, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Robert N. Taub, Columbia University Medical Center; Jonathan J. Lewis, Samus Therapeutics and Molecular Ninja Group; Robert G. Maki, Mount Sinai School of Medicine, New York, NY; Xavier Garcia del Muro, Institut Català d'Oncologia L'Hospitalet, Barcelona, Spain; and Patrick Schöffski, University Hospitals Leuven, Leuven, Belgium.
Anthony D
AD
Elias
Christopher W. Ryan, Oregon Health & Science University, Portland, OR; Ofer Merimsky, Sackler School of Medicine, Tel-Aviv, Israel; Mark Agulnik, Northwestern University, Chicago, IL; Jean-Yves Blay, Centre Léon Bérard, Lyon; Antoine Italiano, Institut Bergonié, Bordeaux, France; Scott M. Schuetze, University of Michigan, Ann Arbor, MI; Brian A. Van Tine, Washington University in St Louis, St Louis, MO; Robin L. Jones and Ian R. Judson, The Royal Marsden Hospital, London, United Kingdom; Anthony D. Elias, University of Colorado-Denver, Aurora, CO; Edwin Choy, Massachusetts General Hospital; Jill Y. Buck and Francois Lebel, ZIOPHARM Oncology, Boston, MA; Thierry Alcindor, McGill University Health Center, Montreal, Quebec, Canada; Vicki L. Keedy, Vanderbilt University Medical Center, Nashville, TN; Damon R. Reed, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Robert N. Taub, Columbia University Medical Center; Jonathan J. Lewis, Samus Therapeutics and Molecular Ninja Group; Robert G. Maki, Mount Sinai School of Medicine, New York, NY; Xavier Garcia del Muro, Institut Català d'Oncologia L'Hospitalet, Barcelona, Spain; and Patrick Schöffski, University Hospitals Leuven, Leuven, Belgium.
Edwin
E
Choy
Christopher W. Ryan, Oregon Health & Science University, Portland, OR; Ofer Merimsky, Sackler School of Medicine, Tel-Aviv, Israel; Mark Agulnik, Northwestern University, Chicago, IL; Jean-Yves Blay, Centre Léon Bérard, Lyon; Antoine Italiano, Institut Bergonié, Bordeaux, France; Scott M. Schuetze, University of Michigan, Ann Arbor, MI; Brian A. Van Tine, Washington University in St Louis, St Louis, MO; Robin L. Jones and Ian R. Judson, The Royal Marsden Hospital, London, United Kingdom; Anthony D. Elias, University of Colorado-Denver, Aurora, CO; Edwin Choy, Massachusetts General Hospital; Jill Y. Buck and Francois Lebel, ZIOPHARM Oncology, Boston, MA; Thierry Alcindor, McGill University Health Center, Montreal, Quebec, Canada; Vicki L. Keedy, Vanderbilt University Medical Center, Nashville, TN; Damon R. Reed, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Robert N. Taub, Columbia University Medical Center; Jonathan J. Lewis, Samus Therapeutics and Molecular Ninja Group; Robert G. Maki, Mount Sinai School of Medicine, New York, NY; Xavier Garcia del Muro, Institut Català d'Oncologia L'Hospitalet, Barcelona, Spain; and Patrick Schöffski, University Hospitals Leuven, Leuven, Belgium.
Thierry
T
Alcindor
Christopher W. Ryan, Oregon Health & Science University, Portland, OR; Ofer Merimsky, Sackler School of Medicine, Tel-Aviv, Israel; Mark Agulnik, Northwestern University, Chicago, IL; Jean-Yves Blay, Centre Léon Bérard, Lyon; Antoine Italiano, Institut Bergonié, Bordeaux, France; Scott M. Schuetze, University of Michigan, Ann Arbor, MI; Brian A. Van Tine, Washington University in St Louis, St Louis, MO; Robin L. Jones and Ian R. Judson, The Royal Marsden Hospital, London, United Kingdom; Anthony D. Elias, University of Colorado-Denver, Aurora, CO; Edwin Choy, Massachusetts General Hospital; Jill Y. Buck and Francois Lebel, ZIOPHARM Oncology, Boston, MA; Thierry Alcindor, McGill University Health Center, Montreal, Quebec, Canada; Vicki L. Keedy, Vanderbilt University Medical Center, Nashville, TN; Damon R. Reed, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Robert N. Taub, Columbia University Medical Center; Jonathan J. Lewis, Samus Therapeutics and Molecular Ninja Group; Robert G. Maki, Mount Sinai School of Medicine, New York, NY; Xavier Garcia del Muro, Institut Català d'Oncologia L'Hospitalet, Barcelona, Spain; and Patrick Schöffski, University Hospitals Leuven, Leuven, Belgium.
Vicki L
VL
Keedy
Christopher W. Ryan, Oregon Health & Science University, Portland, OR; Ofer Merimsky, Sackler School of Medicine, Tel-Aviv, Israel; Mark Agulnik, Northwestern University, Chicago, IL; Jean-Yves Blay, Centre Léon Bérard, Lyon; Antoine Italiano, Institut Bergonié, Bordeaux, France; Scott M. Schuetze, University of Michigan, Ann Arbor, MI; Brian A. Van Tine, Washington University in St Louis, St Louis, MO; Robin L. Jones and Ian R. Judson, The Royal Marsden Hospital, London, United Kingdom; Anthony D. Elias, University of Colorado-Denver, Aurora, CO; Edwin Choy, Massachusetts General Hospital; Jill Y. Buck and Francois Lebel, ZIOPHARM Oncology, Boston, MA; Thierry Alcindor, McGill University Health Center, Montreal, Quebec, Canada; Vicki L. Keedy, Vanderbilt University Medical Center, Nashville, TN; Damon R. Reed, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Robert N. Taub, Columbia University Medical Center; Jonathan J. Lewis, Samus Therapeutics and Molecular Ninja Group; Robert G. Maki, Mount Sinai School of Medicine, New York, NY; Xavier Garcia del Muro, Institut Català d'Oncologia L'Hospitalet, Barcelona, Spain; and Patrick Schöffski, University Hospitals Leuven, Leuven, Belgium.
Damon R
DR
Reed
Christopher W. Ryan, Oregon Health & Science University, Portland, OR; Ofer Merimsky, Sackler School of Medicine, Tel-Aviv, Israel; Mark Agulnik, Northwestern University, Chicago, IL; Jean-Yves Blay, Centre Léon Bérard, Lyon; Antoine Italiano, Institut Bergonié, Bordeaux, France; Scott M. Schuetze, University of Michigan, Ann Arbor, MI; Brian A. Van Tine, Washington University in St Louis, St Louis, MO; Robin L. Jones and Ian R. Judson, The Royal Marsden Hospital, London, United Kingdom; Anthony D. Elias, University of Colorado-Denver, Aurora, CO; Edwin Choy, Massachusetts General Hospital; Jill Y. Buck and Francois Lebel, ZIOPHARM Oncology, Boston, MA; Thierry Alcindor, McGill University Health Center, Montreal, Quebec, Canada; Vicki L. Keedy, Vanderbilt University Medical Center, Nashville, TN; Damon R. Reed, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Robert N. Taub, Columbia University Medical Center; Jonathan J. Lewis, Samus Therapeutics and Molecular Ninja Group; Robert G. Maki, Mount Sinai School of Medicine, New York, NY; Xavier Garcia del Muro, Institut Català d'Oncologia L'Hospitalet, Barcelona, Spain; and Patrick Schöffski, University Hospitals Leuven, Leuven, Belgium.
Robert N
RN
Taub
Christopher W. Ryan, Oregon Health & Science University, Portland, OR; Ofer Merimsky, Sackler School of Medicine, Tel-Aviv, Israel; Mark Agulnik, Northwestern University, Chicago, IL; Jean-Yves Blay, Centre Léon Bérard, Lyon; Antoine Italiano, Institut Bergonié, Bordeaux, France; Scott M. Schuetze, University of Michigan, Ann Arbor, MI; Brian A. Van Tine, Washington University in St Louis, St Louis, MO; Robin L. Jones and Ian R. Judson, The Royal Marsden Hospital, London, United Kingdom; Anthony D. Elias, University of Colorado-Denver, Aurora, CO; Edwin Choy, Massachusetts General Hospital; Jill Y. Buck and Francois Lebel, ZIOPHARM Oncology, Boston, MA; Thierry Alcindor, McGill University Health Center, Montreal, Quebec, Canada; Vicki L. Keedy, Vanderbilt University Medical Center, Nashville, TN; Damon R. Reed, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Robert N. Taub, Columbia University Medical Center; Jonathan J. Lewis, Samus Therapeutics and Molecular Ninja Group; Robert G. Maki, Mount Sinai School of Medicine, New York, NY; Xavier Garcia del Muro, Institut Català d'Oncologia L'Hospitalet, Barcelona, Spain; and Patrick Schöffski, University Hospitals Leuven, Leuven, Belgium.
Antoine
A
Italiano
Christopher W. Ryan, Oregon Health & Science University, Portland, OR; Ofer Merimsky, Sackler School of Medicine, Tel-Aviv, Israel; Mark Agulnik, Northwestern University, Chicago, IL; Jean-Yves Blay, Centre Léon Bérard, Lyon; Antoine Italiano, Institut Bergonié, Bordeaux, France; Scott M. Schuetze, University of Michigan, Ann Arbor, MI; Brian A. Van Tine, Washington University in St Louis, St Louis, MO; Robin L. Jones and Ian R. Judson, The Royal Marsden Hospital, London, United Kingdom; Anthony D. Elias, University of Colorado-Denver, Aurora, CO; Edwin Choy, Massachusetts General Hospital; Jill Y. Buck and Francois Lebel, ZIOPHARM Oncology, Boston, MA; Thierry Alcindor, McGill University Health Center, Montreal, Quebec, Canada; Vicki L. Keedy, Vanderbilt University Medical Center, Nashville, TN; Damon R. Reed, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Robert N. Taub, Columbia University Medical Center; Jonathan J. Lewis, Samus Therapeutics and Molecular Ninja Group; Robert G. Maki, Mount Sinai School of Medicine, New York, NY; Xavier Garcia del Muro, Institut Català d'Oncologia L'Hospitalet, Barcelona, Spain; and Patrick Schöffski, University Hospitals Leuven, Leuven, Belgium.
Xavier
X
Garcia Del Muro
Christopher W. Ryan, Oregon Health & Science University, Portland, OR; Ofer Merimsky, Sackler School of Medicine, Tel-Aviv, Israel; Mark Agulnik, Northwestern University, Chicago, IL; Jean-Yves Blay, Centre Léon Bérard, Lyon; Antoine Italiano, Institut Bergonié, Bordeaux, France; Scott M. Schuetze, University of Michigan, Ann Arbor, MI; Brian A. Van Tine, Washington University in St Louis, St Louis, MO; Robin L. Jones and Ian R. Judson, The Royal Marsden Hospital, London, United Kingdom; Anthony D. Elias, University of Colorado-Denver, Aurora, CO; Edwin Choy, Massachusetts General Hospital; Jill Y. Buck and Francois Lebel, ZIOPHARM Oncology, Boston, MA; Thierry Alcindor, McGill University Health Center, Montreal, Quebec, Canada; Vicki L. Keedy, Vanderbilt University Medical Center, Nashville, TN; Damon R. Reed, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Robert N. Taub, Columbia University Medical Center; Jonathan J. Lewis, Samus Therapeutics and Molecular Ninja Group; Robert G. Maki, Mount Sinai School of Medicine, New York, NY; Xavier Garcia del Muro, Institut Català d'Oncologia L'Hospitalet, Barcelona, Spain; and Patrick Schöffski, University Hospitals Leuven, Leuven, Belgium.
Ian R
IR
Judson
Christopher W. Ryan, Oregon Health & Science University, Portland, OR; Ofer Merimsky, Sackler School of Medicine, Tel-Aviv, Israel; Mark Agulnik, Northwestern University, Chicago, IL; Jean-Yves Blay, Centre Léon Bérard, Lyon; Antoine Italiano, Institut Bergonié, Bordeaux, France; Scott M. Schuetze, University of Michigan, Ann Arbor, MI; Brian A. Van Tine, Washington University in St Louis, St Louis, MO; Robin L. Jones and Ian R. Judson, The Royal Marsden Hospital, London, United Kingdom; Anthony D. Elias, University of Colorado-Denver, Aurora, CO; Edwin Choy, Massachusetts General Hospital; Jill Y. Buck and Francois Lebel, ZIOPHARM Oncology, Boston, MA; Thierry Alcindor, McGill University Health Center, Montreal, Quebec, Canada; Vicki L. Keedy, Vanderbilt University Medical Center, Nashville, TN; Damon R. Reed, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Robert N. Taub, Columbia University Medical Center; Jonathan J. Lewis, Samus Therapeutics and Molecular Ninja Group; Robert G. Maki, Mount Sinai School of Medicine, New York, NY; Xavier Garcia del Muro, Institut Català d'Oncologia L'Hospitalet, Barcelona, Spain; and Patrick Schöffski, University Hospitals Leuven, Leuven, Belgium.
Jill Y
JY
Buck
Christopher W. Ryan, Oregon Health & Science University, Portland, OR; Ofer Merimsky, Sackler School of Medicine, Tel-Aviv, Israel; Mark Agulnik, Northwestern University, Chicago, IL; Jean-Yves Blay, Centre Léon Bérard, Lyon; Antoine Italiano, Institut Bergonié, Bordeaux, France; Scott M. Schuetze, University of Michigan, Ann Arbor, MI; Brian A. Van Tine, Washington University in St Louis, St Louis, MO; Robin L. Jones and Ian R. Judson, The Royal Marsden Hospital, London, United Kingdom; Anthony D. Elias, University of Colorado-Denver, Aurora, CO; Edwin Choy, Massachusetts General Hospital; Jill Y. Buck and Francois Lebel, ZIOPHARM Oncology, Boston, MA; Thierry Alcindor, McGill University Health Center, Montreal, Quebec, Canada; Vicki L. Keedy, Vanderbilt University Medical Center, Nashville, TN; Damon R. Reed, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Robert N. Taub, Columbia University Medical Center; Jonathan J. Lewis, Samus Therapeutics and Molecular Ninja Group; Robert G. Maki, Mount Sinai School of Medicine, New York, NY; Xavier Garcia del Muro, Institut Català d'Oncologia L'Hospitalet, Barcelona, Spain; and Patrick Schöffski, University Hospitals Leuven, Leuven, Belgium.
Francois
F
Lebel
Christopher W. Ryan, Oregon Health & Science University, Portland, OR; Ofer Merimsky, Sackler School of Medicine, Tel-Aviv, Israel; Mark Agulnik, Northwestern University, Chicago, IL; Jean-Yves Blay, Centre Léon Bérard, Lyon; Antoine Italiano, Institut Bergonié, Bordeaux, France; Scott M. Schuetze, University of Michigan, Ann Arbor, MI; Brian A. Van Tine, Washington University in St Louis, St Louis, MO; Robin L. Jones and Ian R. Judson, The Royal Marsden Hospital, London, United Kingdom; Anthony D. Elias, University of Colorado-Denver, Aurora, CO; Edwin Choy, Massachusetts General Hospital; Jill Y. Buck and Francois Lebel, ZIOPHARM Oncology, Boston, MA; Thierry Alcindor, McGill University Health Center, Montreal, Quebec, Canada; Vicki L. Keedy, Vanderbilt University Medical Center, Nashville, TN; Damon R. Reed, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Robert N. Taub, Columbia University Medical Center; Jonathan J. Lewis, Samus Therapeutics and Molecular Ninja Group; Robert G. Maki, Mount Sinai School of Medicine, New York, NY; Xavier Garcia del Muro, Institut Català d'Oncologia L'Hospitalet, Barcelona, Spain; and Patrick Schöffski, University Hospitals Leuven, Leuven, Belgium.
Jonathan J
JJ
Lewis
Christopher W. Ryan, Oregon Health & Science University, Portland, OR; Ofer Merimsky, Sackler School of Medicine, Tel-Aviv, Israel; Mark Agulnik, Northwestern University, Chicago, IL; Jean-Yves Blay, Centre Léon Bérard, Lyon; Antoine Italiano, Institut Bergonié, Bordeaux, France; Scott M. Schuetze, University of Michigan, Ann Arbor, MI; Brian A. Van Tine, Washington University in St Louis, St Louis, MO; Robin L. Jones and Ian R. Judson, The Royal Marsden Hospital, London, United Kingdom; Anthony D. Elias, University of Colorado-Denver, Aurora, CO; Edwin Choy, Massachusetts General Hospital; Jill Y. Buck and Francois Lebel, ZIOPHARM Oncology, Boston, MA; Thierry Alcindor, McGill University Health Center, Montreal, Quebec, Canada; Vicki L. Keedy, Vanderbilt University Medical Center, Nashville, TN; Damon R. Reed, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Robert N. Taub, Columbia University Medical Center; Jonathan J. Lewis, Samus Therapeutics and Molecular Ninja Group; Robert G. Maki, Mount Sinai School of Medicine, New York, NY; Xavier Garcia del Muro, Institut Català d'Oncologia L'Hospitalet, Barcelona, Spain; and Patrick Schöffski, University Hospitals Leuven, Leuven, Belgium.
Robert G
RG
Maki
Christopher W. Ryan, Oregon Health & Science University, Portland, OR; Ofer Merimsky, Sackler School of Medicine, Tel-Aviv, Israel; Mark Agulnik, Northwestern University, Chicago, IL; Jean-Yves Blay, Centre Léon Bérard, Lyon; Antoine Italiano, Institut Bergonié, Bordeaux, France; Scott M. Schuetze, University of Michigan, Ann Arbor, MI; Brian A. Van Tine, Washington University in St Louis, St Louis, MO; Robin L. Jones and Ian R. Judson, The Royal Marsden Hospital, London, United Kingdom; Anthony D. Elias, University of Colorado-Denver, Aurora, CO; Edwin Choy, Massachusetts General Hospital; Jill Y. Buck and Francois Lebel, ZIOPHARM Oncology, Boston, MA; Thierry Alcindor, McGill University Health Center, Montreal, Quebec, Canada; Vicki L. Keedy, Vanderbilt University Medical Center, Nashville, TN; Damon R. Reed, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Robert N. Taub, Columbia University Medical Center; Jonathan J. Lewis, Samus Therapeutics and Molecular Ninja Group; Robert G. Maki, Mount Sinai School of Medicine, New York, NY; Xavier Garcia del Muro, Institut Català d'Oncologia L'Hospitalet, Barcelona, Spain; and Patrick Schöffski, University Hospitals Leuven, Leuven, Belgium.
Patrick
P
Schöffski
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009362:Neoplasm Metastasis; D010752:Phosphoramide Mustards / Q000008:administration & dosage / Q000009:adverse effects; D010919:Placebos; D012509:Sarcoma / Q000188:drug therapy* / Q000473:pathology
D010752:Phosphoramide Mustards; D010919:Placebos; C027061:isophosphamide mustard; D004317:Doxorubicin